Beetroot Extract: Dietary Nitrate and Blood Pressure Lowering Evidence

This article is for informational purposes only and does not constitute medical advice. Always consult your cardiologist, internist, or healthcare provider before starting any supplement, especially if you have a diagnosed heart condition or take cardiovascular medications. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

SterlingMedicalCenter.org Research Team | July 2026

Beetroot Extract: Dietary Nitrate and Blood Pressure Lowering Evidence

Beetroot's Mechanism in Cardiovascular Health

Beetroot extract is a concentrated source of dietary inorganic nitrate, which is converted to nitrite by oral bacteria and subsequently to nitric oxide (NO) in vascular tissue—leading to vasodilation and blood pressure reduction. This represents an alternative pathway to NO production independent of endothelial nitric oxide synthase (eNOS), particularly valuable in patients with endothelial dysfunction where eNOS-mediated NO synthesis is impaired. Research demonstrates consistent blood pressure-lowering effects and shows promising data for exercise capacity improvement in heart failure and coronary artery disease patients.

Biochemistry of Dietary Nitrate and the Nitrate-Nitrite-NO Pathway

Beetroots accumulate high concentrations of inorganic nitrate (NO3−) as a natural nitrogen storage compound. When consumed, nitrate is absorbed in the small intestine and circulates systemically. Approximately 20-25% is excreted unchanged, while 75% is actively taken up by the salivary glands and secreted into saliva. Oral bacteria containing nitrate reductase enzymes convert nitrate to nitrite (NO2−). Nitrite is then swallowed and reduced to NO in the stomach (via acidification) and in vascular tissue (via mitochondrial and enzymatic pathways). This nitrate-nitrite-NO pathway is particularly important in hypoxic and acidic conditions—precisely the hemodynamic milieu of heart failure and coronary artery disease. Unlike the eNOS pathway, this route of NO generation is preserved in endothelial dysfunction and occurs even when eNOS is uncoupled or deficient. Beetroot extract typically delivers 400-1000mg nitrate per dose.

Cardiovascular Research: Blood Pressure and Exercise Physiology

Blood Pressure Reduction. This is the most robust evidence base for beetroot extract. A 2015 meta-analysis of 14 RCTs (n=701) found that beetroot juice or extract supplementation (containing 500-1000mg inorganic nitrate) reduced systolic BP by 3-6 mmHg and diastolic BP by 1-3 mmHg. Effects were consistent across hypertensive and normotensive populations, though hypertensive patients showed slightly larger reductions. The response onset was rapid—BP reductions appeared within 24 hours of a single dose. A notable study (2013) of stage 1 hypertensive patients assigned to 500mg nitrate (beetroot extract) daily showed a 7.7 mmHg systolic reduction over 4 weeks, comparable to some antihypertensive monotherapies. Evidence demonstrates vasodilation independent of eNOS function, making beetroot particularly useful in populations with endothelial dysfunction. Evidence grade: Strong. The effect is modest but consistent and clinically meaningful as adjunctive therapy.

Exercise Capacity and Oxygen Efficiency. Multiple studies show that dietary nitrate improves exercise performance and reduces oxygen consumption during submaximal exercise. A 2015 RCT of 18 heart failure patients found that 500mg daily beetroot extract improved six-minute walk distance by 22 meters and reduced dyspnea ratings. The mechanism involves reduced mitochondrial oxygen cost during muscle contraction, allowing greater work output at lower oxygen consumption. Athletes using nitrate supplementation demonstrate 2-3% improvements in endurance capacity and time-to-exhaustion. Cardiac patients with reduced exercise tolerance (post-MI, heart failure, coronary stenosis) show meaningful functional improvements with beetroot supplementation. Evidence grade: Moderate. Clinical significance: a 20-meter improvement in six-minute walk test represents meaningful enhancement of daily functional capacity for heart failure patients.

Endothelial Function and Arterial Stiffness. Flow-mediated dilation (FMD) and pulse wave velocity (PWV) are validated markers of vascular health. Studies demonstrate that beetroot extract improves FMD by 1-2 percentage points and reduces PWV by 0.3-0.5 m/s in patients with hypertension and cardiovascular disease. Arterial stiffness reduction is important because increased aortic stiffness is an independent predictor of cardiovascular events and heart failure progression. A small mechanistic study (2014) found that 500mg daily nitrate reduced central aortic stiffness and reduced reflected wave augmentation, indicating improved vascular compliance. Evidence grade: Moderate. These findings suggest that beetroot's effects extend beyond acute vasodilation to vascular remodeling and improved arterial compliance over time.

Antiplatelet Effects. Nitrite and NO inhibit platelet aggregation and reduce thromboxane A2 synthesis. In vitro studies show that incubating platelets with beetroot extract or nitrite reduces aggregation by 15-20%. A small clinical trial (2013) found reduced collagen-induced platelet aggregation in healthy volunteers receiving dietary nitrate. However, clinical outcomes trials demonstrating thrombotic event reduction are lacking. Evidence grade: Preliminary. For cardiac patients, this potential antiplatelet benefit must be weighed against interaction risks with antiplatelet medications (see drug interactions below).

Dose Mathematics and Product Selection

Clinical trials demonstrating cardiovascular benefit used 500-1000mg daily inorganic nitrate, typically delivered as beetroot juice (approximately 250ml of commercial beet juice contains 400-600mg nitrate) or as concentrated beetroot extract powders/supplements (400-1000mg nitrate per dose). Over-the-counter beetroot supplements vary widely in nitrate content; many “beetroot extracts” are marketed for sports performance and deliver minimal nitrate. For cardiac patients, selecting products verified to contain ≥500mg nitrate per serving is essential. Total daily dosing should be 500-1000mg for cardiovascular benefit. Once-daily dosing (500mg morning) or twice-daily (250-500mg morning and evening) are practical approaches.

Forms and Bioavailability Optimization

Beetroot is available in three forms: fresh juice, concentrated juice extract, and powdered extract. Fresh juice is most bioavailable but requires refrigeration and large volumes (500ml juice = 5mg per liter calories). Concentrated extracts (400-1000mg nitrate in capsule or powder) are practical for cardiac patients. Powdered forms have excellent stability and shelf-life. Critical point: oral nitrate bioavailability depends on intact oral microbiota capable of nitrate reduction. Antimicrobial mouthwash, excessive oral antiseptics, or antibiotic use can impair the nitrate-to-nitrite conversion, reducing NO production. Cardiac patients using antimicrobial mouthwash should avoid it during beetroot supplementation periods or ensure at least 4-hour separation.

Drug Interactions and Cardiac Medication Compatibility

Nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate). This is the major potential interaction. Both dietary nitrate and prescription nitrates increase NO and cause vasodilation. Additive effects may produce excessive hypotension, particularly in volume-depleted states. However, clinical evidence of significant adverse interaction is limited. Most cardiologists allow concurrent use with monitoring for orthostatic hypotension and dizziness. If a cardiac patient is on chronic nitrate therapy, starting beetroot should be done gradually with BP monitoring.

Phosphodiesterase-5 inhibitors (sildenafil, tadalafil). Similar mechanism to nitrates—enhancement of NO-cGMP signaling. Combined use increases vasodilation. Case reports exist of syncope with combined nitrate + PDE-5 inhibitor use; adding dietary nitrate to this combination warrants caution. Blood pressure and symptom monitoring are essential.

Antihypertensive medications (ACE-I, ARB, beta-blockers, calcium channel blockers, diuretics). Additive blood pressure-lowering effects. Patients on multiple antihypertensives should have BP monitored when starting beetroot. Dose reductions of existing medications may be needed to prevent hypotension.

Antiplatelet agents (aspirin, clopidogrel) and anticoagulants (warfarin, DOACs). Dietary nitrate has mild antiplatelet activity. Combining with aspirin or clopidogrel may increase bleeding risk slightly. However, clinical evidence of significant additive effect is limited. Consistency of beetroot intake is important; avoid rapid changes in dosing that could affect anticoagulation stability.

Who Should Consider Beetroot Extract / Contraindications

Should consider: Patients with stage 1 or 2 hypertension (systolic 140-160 mmHg) seeking adjunctive therapy, post-MI patients with reduced exercise tolerance, heart failure patients (HFrEF or HFpEF) with dyspnea on exertion, coronary artery disease patients with angina or functional limitation, patients with endothelial dysfunction and normal BP (seeking vascular health optimization), athletes or active cardiac patients seeking exercise performance enhancement without banned substances.

Should avoid or use cautiously: Patients with symptomatic hypotension or severe aortic stenosis, patients on multiple nitrate sources or PDE-5 inhibitors (risk of excessive vasodilation), patients with nitrate tolerance from chronic nitroglycerin use (cross-tolerance with dietary nitrate possible), patients on anticoagulation at dose limits requiring INR stability (though interaction risk is low), patients with significant renal impairment (eGFR <30 mL/min—accumulation of nitrate metabolites possible). Beetroot is generally safe in these populations with monitoring but not first-line choices.

Clinical Bottom Line for Cardiac Patients

Beetroot extract has strong evidence for blood pressure reduction and moderate evidence for improving endothelial function and exercise capacity in cardiac patients. Unlike pharmaceutical vasodilators or eNOS-dependent supplements, dietary nitrate works through an alternative pathway preserved in endothelial dysfunction, making it particularly valuable in advanced atherosclerosis and heart failure. Clinical dosing (500-1000mg daily nitrate) is achievable through commercially available extracts. Beetroot complements other NO-enhancing strategies such as L-citrulline and endothelial-protective compounds. The evidence supports beetroot as an adjunctive antihypertensive and functional enhancement supplement for cardiac populations, though it should not replace guideline-directed pharmacotherapy. Rapid onset of effect (24 hours) makes beetroot practical for cardiac patients seeking functional improvement.

Practical Implementation for Cardiac Teams

Incorporating beetroot into a cardiac patient's regimen requires baseline BP assessment, medication review for nitrate/PDE-5 inhibitor use, and monitoring at 2-4 weeks for hypotension. Functional assessment (six-minute walk distance, dyspnea rating) should be performed at baseline and 4-8 weeks to objectively measure benefit. If BP reduction is excessive or symptoms of orthostatic hypotension develop, existing antihypertensive doses should be adjusted downward.

This ingredient profile is provided for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a substitute for evaluation by a qualified cardiologist, internist, or healthcare provider. Cardiac patients should discuss all supplement use with their cardiology care team before starting, stopping, or changing any supplement. Individual responses to supplements vary. SterlingMedicalCenter.org is an independent editorial publication and is not affiliated with any hospital, clinic, cardiology practice, or medical provider.